샘플 요청 목록

 카트 문의
시장보고서
상품코드
1944397

사르코이드증 치료제 시장 : 작용기서별, 투여 경로별, 약제별, 유형별, 최종 용도별, 연령층별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2025-2032년)

Sarcoidosis Drug Market, By Mechanism of Action, By Route of Administration, By Drug, By Type, By End-Use, By Age Group, By Indication, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 329 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

사르코이드증 치료제 시장 규모는 2024년에 72억 110만 달러로 평가되며, 2025-2032년에 CAGR 6.12%로 확대할 전망입니다.

유육종증 치료제 시장에는 폐, 피부, 림프절 등의 장기에 육아종 형성을 특징으로 하는 염증성 질환인 유육종증 치료에 사용되는 의약품이 포함됩니다. 자가면역질환 및 염증성 질환의 유병률 증가, 진단율 향상, 임상적 인식 개선 등이 시장 성장의 주요 촉진요인으로 작용하고 있습니다. 부작용을 줄이기 위해 시장에서는 장기적인 코르티코스테로이드 사용에서 면역억제제나 생물제제로의 전환이 점차 진행되고 있습니다. 그러나 승인된 질환 특이적 약물이 적고, 질환의 이질성이 여전히 큰 장벽으로 작용하고 있습니다. 그럼에도 불구하고 진행 중인 임상 연구, 희귀질환 치료제(희귀의약품) 개발, 표적 생물제제 개발을 통해 환자의 장기적인 결과와 치료의 정확성을 향상시킬 수 있는 기회가 생겨나고 있습니다.

유육종증 치료제 시장 역학

연구개발에 대한 집중력 강화

유육종증 치료제 시장은 새로운 치료법의 발전과 환자 예후 개선을 위한 집중적인 연구개발 노력으로 인해 점점 더 큰 시장을 형성하고 있습니다. 이러한 초점은 질병의 임상적 복잡성을 더 잘 관리하기 위한 표적 치료와 맞춤형 의료 접근법의 도입을 촉진하고 있습니다. 현재 치료는 주로 코르티코 스테로이드와 면역 억제제의 적응증 외 사용에 의존하고 있으며, 이는 종종 안전성 문제 및 치료 효과의 편차와 관련이 있습니다. 그 결과, 대체 치료 옵션의 개발은 여전히 중요한 우선순위입니다.

예를 들어 2025년 2월, 로이반트 사이언스는 피부 유육종증 성인 환자를 대상으로 경구용 듀얼 TYK2/JAK1 억제제인 브레포시티닙의 임상 2상 시험 계획을 발표했습니다. 본 시험은 2026년 4월에 시작될 예정이며, 결과는 2026년 하반기에 나올 것으로 예측됩니다.

유육종증 치료제 시장 : 세분화 분석

세계 유육종증 치료제 시장은 작용기전, 투여 경로, 약물, 유형, 최종 용도, 연령대, 적응증, 지역에 따라 세분화되어 있습니다.

폐육종증 분야는 폐에 육아종이 관찰되는 특징을 가지고 있고, 가장 흔한 유형의 육종증(환자의 90%를 차지)이기 때문에 육종증 치료제 시장에서 큰 비중을 차지하고 있습니다. 이러한 높은 유병률은 폐 증상에 대한 표적 치료와 조사의 필요성을 강조하고 있습니다. 시장에서의 우위는 높은 유병률, 혁신적인 치료법에 대한 지속적인 연구, 의료진과 환자들의 인식 개선과 관련이 있습니다. 폐고혈압이나 영구적인 폐섬유증과 같은 심각한 질환은 표적 치료의 필요성을 강조하고 있습니다. 2022년 11월, 키네반트 사이언스는 GM-CSF를 표적으로 하는 모노클로널 항체 '나밀루맙'의 폐육종증 치료 효과를 평가하는 RESOLVE-Lung 임상을 시작했습니다. 107명의 참가자를 대상으로 한 이번 임상시험은 2024년 말까지 예비 결과를 얻을 수 있을 것으로 예측됩니다.

약물별로는 프레드니손이 2025년 유육종증 치료제 시장을 독점할 것으로 예측됩니다. 이는 유육종증의 주요 치료제로 널리 인정받고 있기 때문입니다. 코르티코스테로이드로서 특히 호흡기 증상에서 면역반응, 염증, 증상을 감소시킵니다. 임상 가이드라인에서는 일관되게 프레드니손을 표준 치료제로 권고하고 있으며, 기초 치료제로서의 중요성을 강조하고 있습니다. 광범위한 수용성, 저렴한 가격, 임상 현장에서의 친숙함으로 인해 의료 전문가들의 장기적인 치료 옵션으로 인기를 끌고 있습니다. 프레드니손의 염증 관리 효과와 보급이 결합하여 시장에서 우위를 점하게 되었습니다. 2020년 연구에 따르면 유육종증 환자의 59.3%가 코르티코스테로이드 치료를 받고 있으며, 그 중 24.7%가 장기 치료를 받고 있습니다. 장기 사용과 심각한 부작용이 결합되어 보다 안전하고 효과적인 치료법의 필요성이 강조되고 있습니다.

유육종증 치료제 시장 - 지역별 분석

북미는 높은 유병률, 특히 심장병변을 동반한 사례의 높은 유병률, 탄탄한 의료 인프라, 활발한 연구개발 프로그램, 제약사, 학계, 의료 전문가, 환자 지원 단체 간의 협력으로 인해 유육종증 치료제 시장에서 큰 점유율을 차지하고 있습니다. 이 지역의 잘 구축된 의료 인프라는 유육종증의 조기 발견과 철저한 관리를 가능하게 하며, 환자들에게 전문적인 치료와 최신 의약품을 제공합니다. 유육종증 치료는 주요 제약회사와 연구기관이 지식 공유와 질병 관리의 가속화를 위해 협력하면서 진전을 거듭하고 있습니다.

2024년 4월, Sarcoidosis Research Foundation은 Walgreens와 협력하여 앨라배마 주에서 Sarcoidosis에 대한 인식을 높이고 봄철 예방접종을 장려하기 위해 노력했습니다. 지역사회에 미치는 영향을 강조하고, 연구 및 환자 지원 구상에 대한 기부를 요청했습니다.

미국 유육종증 치료제 시장 - 국가별 분석

2024년 미국 유육종증 치료제 시장은 북미에서 가장 큰 매출 점유율을 차지했습니다. 이는 특히 중증화되기 쉬운 아프리카계 미국인의 높은 발병률과 더불어 잘 정비된 의료 시스템, 광범위한 연구개발 활동, 주요 제약사의 강력한 존재감이 결합되어 이루어낸 결과입니다. 미국 환자들은 첨단 진단 기술, 새로운 생물제제 및 희귀질환 치료제를 포함한 다양한 치료법을 이용할 수 있습니다. 유육종증 연구에 대한 강력한 자금 지원과 학계 및 업계 관계자들과의 전략적 협력은 시장 성장을 주도하고 있으며, 미국을 유육종증 치료제 개발 및 도입의 선두주자로 자리매김하고 있습니다.

목차

제1장 사르코이드증 치료제 시장의 개요

제2장 개요

제3장 사르코이드증 치료제의 주요 시장 동향

제4장 사르코이드증 치료제 시장 : 산업 분석

제5장 사르코이드증 치료제 시장 : 높아지는 지정학적 긴장의 영향

제6장 사르코이드증 치료제 시장 구도

제7장 사르코이드증 치료제 시장 : 작용기서별

제8장 사르코이드증 치료제 시장 : 투여 경로별

제9장 사르코이드증 치료제 시장 : 약제별

제10장 사르코이드증 치료제 시장 : 유형별

제11장 사르코이드증 치료제 시장 : 최종 용도별

제12장 사르코이드증 치료제 시장 : 연령층별

제13장 사르코이드증 치료제 시장 : 적응증별

제14장 사르코이드증 치료제 시장 : 지역별

제15장 주요 벤더 분석 : 사르코이드증 치료제 산업

제16장 애널리스트에 의한 전방위 전망

KSA

Sarcoidosis Drug Market size was valued at US$ 7,201.10 Million in 2024, expanding at a CAGR of 6.12% from 2025 to 2032.

The Sarcoidosis Drug Market includes pharmaceutical therapies used to treat sarcoidosis, an inflammatory disease characterized by granuloma formation in organs such as the lungs, skin, and lymph nodes. The rising prevalence of autoimmune and inflammatory disorders, increased diagnosis rates, and improved clinical awareness are the primary drivers of market growth. To reduce side effects, the market is gradually shifting away from long-term corticosteroid use and toward immunosuppressants and biologic therapies. However, there are few disease-specific drugs that have been approved, and disease heterogeneity is still a major barrier. Despite this, opportunities are emerging through ongoing clinical research, orphan drug development, and targeted biologics to improve long-term patient outcomes and treatment precision.

Sarcoidosis Drug Market- Market Dynamics

Increased emphasis on research and development

The sarcoidosis drug market is increasingly shaped by intensive research and development efforts aimed at advancing novel therapies and enhancing patient outcomes. This focus has encouraged the adoption of targeted treatments and personalized medicine approaches to better manage the disease's clinical complexity. At present, treatment largely depends on the off-label use of corticosteroids and immunosuppressants, which are often associated with safety concerns and variable therapeutic effectiveness. Consequently, the development of alternative treatment options remains a critical priority.

For instance, in February 2025, Roivant Sciences announced plans to initiate a Phase II clinical trial of brepocitinib, an oral dual TYK2 and JAK1 inhibitor, for the treatment of adults with cutaneous sarcoidosis. The study is scheduled to commence in April 2026, with results anticipated in the latter half of 2026.

Sarcoidosis Drug Market- Segmentation Analysis:

The Global Sarcoidosis Drug Market is segmented on the basis of Mechanism of Action, Route of Administration, Drug, Type, End-Use, Age Group, Indication, and Region.

The pulmonary sarcoidosis segment accounts for a significant share of the sarcoidosis drug market because it is distinguished by the presence of granulomas in the lungs and is the most common type of sarcoidosis, affecting 90% of people. The high prevalence highlights the need for targeted treatments and investigations into pulmonary symptoms. Market dominance is associated with higher prevalence rates, ongoing research into innovative therapies, and increased awareness among healthcare providers and patients. Serious conditions like pulmonary hypertension and permanent lung fibrosis highlight the need for targeted treatments. In November 2022, Kinevant Sciences initiated the RESOLVE-Lung study to evaluate namilumab, a monoclonal antibody that targets GM-CSF, for the treatment of pulmonary sarcoidosis. The study, which included 107 participants, is expected to produce preliminary findings by the end of 2024.

Based on the Drug: Prednisone dominate the sarcoidosis drug market in 2025 because it is widely recognized as the primary treatment for sarcoidosis. As a corticosteroid, it reduces immune response, inflammation, and symptoms, particularly in respiratory cases. Clinical guidelines consistently recommend prednisone as the standard therapy, emphasizing its importance as a foundational treatment. Its widespread acceptance, affordability, and clinical familiarity make it a popular choice among healthcare professionals for prolonged treatment. Prednisone's effectiveness in inflammation management, combined with its widespread use, contributed to its market prevalence. According to the 2020 study, 59.3% of sarcoidosis patients are treated with corticosteroids, while 24.7% receive long-term treatment. The prolonged use, combined with significant side effects, emphasizes the need for safer and more effective treatment options.

Sarcoidosis Drug Market- Geographical Insights

North America holds significant share in the sarcoidosis drug market due to its high prevalence, especially with cardiac involvement, robust healthcare infrastructure, active research and development programs, and partnerships between pharmaceutical companies, academic entities, healthcare professionals, and patient advocacy organizations. The region's well-established healthcare infrastructure allows early detection and thorough management of sarcoidosis, providing patients with specialized treatment and the latest medicines. Sarcoidosis therapy advances with major pharmaceutical companies and research organizations, which collaborate to share knowledge and accelerate disease management.

In April 2024, the Foundation for Sarcoidosis Research partnered with Walgreens to raise sarcoidosis awareness and promote spring vaccinations in Alabama, emphasizing community impact and encouraging donations to research and patient assistance initiatives.

United States Sarcoidosis Drug Market- Country Insights

The U.S. sarcoidosis drug market accounted for a sizable revenue share in North America in 2024, owing to the disease's high prevalence, particularly among African Americans, who frequently suffer from more severe forms of the disease. This is complemented by a well-developed healthcare system, extensive research and development activities, and a strong presence of major pharmaceutical corporations. Patients in the United States have access to advanced diagnostics and a wide range of therapies, including novel biologics and orphan drugs. Strong funding for sarcoidosis research, as well as strategic collaborations between academic institutions and industry players, are driving market growth and establishing the United States as a leader in sarcoidosis drug development and adoption.

Sarcoidosis Drug Market- Competitive Landscape:

The sarcoidosis drug market is moderately competitive, with established pharmaceutical companies and emerging players offering anti-inflammatory, immunosuppressive, and biologic therapies. Market participants compete primarily based on product efficacy, safety profiles, and expanded indications. Corticosteroids remain the primary first-line treatment, but immunosuppressants and biologics are gaining popularity for chronic and refractory cases. Companies are also investing in clinical trials and pipeline expansion to meet unmet medical needs, particularly for steroid-free treatments. Strategic collaborations, research partnerships, and regulatory approvals all play an important role in maintaining market positions. Key players in the sarcoidosis drug market include Novartis AG, Kinevant Sciences GmbH, Molecure S.A, aTyr Pharma, all of which rely on strong R&D capabilities and global distribution networks to stay competitive.

In November 2024, The Foundation for Sarcoidosis Research awarded Dr. Eliot Peyster and Dr. Ravi Karra USD 100,000 to advance the diagnosis and treatment of cardiac sarcoidosis, with a focus on establishing new diagnostic benchmarks and reusing imaging agents.

Recent Developments:

In April 2024, aTyr Pharma has launched a global Phase III EFZO-FIT(TM) trial to assess efzofitimod, an innovative treatment aimed at neuropilin-2 for pulmonary sarcoidosis that has been granted orphan drug designations in the U.S., EU, and Japan.

In March 2025, Xentria, Inc. reported significant progress in its XTMAB-16 study for pulmonary sarcoidosis, including the successful enrollment of patients in the dose-ranging study. XTMAB-16 is a new anti-TNF-a monoclonal antibody being developed as a potential treatment for pulmonary sarcoidosis. This advancement demonstrates Xentria's commitment to addressing the unmet need for targeted therapies in sarcoidosis, with the next phase of research, which will include additional patient screening, set to begin in Fall 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SARCOIDOSIS DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Pfizer Inc
  • Amgen Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Kinevant Sciences GmbH
  • Molecure S.A
  • aTyr Pharma
  • Merck & Co., Inc
  • Xentria
  • United Therapeutics Corporation
  • Relief Therapeutics
  • Mallinckrodt
  • AbbVie Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • GSK plc.
  • Theravance Biopharma
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antimalarial
  • Immunosuppressants
  • Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
  • Corticosteroid

GLOBAL SARCOIDOSIS DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Injectable
  • Oral
  • Topical

GLOBAL SARCOIDOSIS DRUG MARKET, BY DRUG- MARKET ANALYSIS, 2019 - 2032

  • Hydroxychloroquine
  • Azathioprine
  • Corticotropin
  • Dexamethasone
  • Colchicine
  • Chloroquine
  • Prednisone
  • Methotrexate
  • Deltasone

GLOBAL SARCOIDOSIS DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hepatic Sarcoidosis
  • Renal Sarcoidosis
  • Sarcoidosis of the Spleen and Bone Marrow
  • Pulmonary Sarcoidosis
  • Musculoskeletal Sarcoidosis
  • Cutaneous Sarcoidosis
  • Ocular Sarcoidosis
  • Cardiac Sarcoidosis
  • Neurosarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Surgical Centers
  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Pediatric
  • Adult
  • Geriatric

GLOBAL SARCOIDOSIS DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Extrapulmonary Sarcoidosis
  • Pulmonary Sarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Sarcoidosis Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sarcoidosis Drug Market Snippet by Mechanism of Action
    • 2.1.2. Sarcoidosis Drug Market Snippet by Route of Administration
    • 2.1.3. Sarcoidosis Drug Market Snippet by Drug
    • 2.1.4. Sarcoidosis Drug Market Snippet by Type
    • 2.1.5. Sarcoidosis Drug Market Snippet by End-Use
    • 2.1.6. Sarcoidosis Drug Market Snippet by Age Group
    • 2.1.7. Sarcoidosis Drug Market Snippet by Indication
    • 2.1.8. Sarcoidosis Drug Market Snippet by Country
    • 2.1.9. Sarcoidosis Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Sarcoidosis Drug Key Market Trends

  • 3.1. Sarcoidosis Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sarcoidosis Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sarcoidosis Drug Market Opportunities
  • 3.4. Sarcoidosis Drug Market Future Trends

4. Sarcoidosis Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sarcoidosis Drug Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Sarcoidosis Drug Market Landscape

  • 6.1. Sarcoidosis Drug Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sarcoidosis Drug Market - By Mechanism of Action

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 7.1.2. Antimalarial
    • 7.1.3. Immunosuppressants
    • 7.1.4. Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
    • 7.1.5. Corticosteroid

8. Sarcoidosis Drug Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Injectable
    • 8.1.3. Oral
    • 8.1.4. Topical

9. Sarcoidosis Drug Market - By Drug

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug, 2024 & 2032 (%)
    • 9.1.2. Hydroxychloroquine
    • 9.1.3. Azathioprine
    • 9.1.4. Corticotropin
    • 9.1.5. Dexamethasone
    • 9.1.6. Colchicine
    • 9.1.7. Chloroquine
    • 9.1.8. Prednisone
    • 9.1.9. Methotrexate
    • 9.1.10. Deltasone

10. Sarcoidosis Drug Market - By Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 10.1.2. Hepatic Sarcoidosis
    • 10.1.3. Renal Sarcoidosis
    • 10.1.4. Sarcoidosis of the Spleen and Bone Marrow
    • 10.1.5. Pulmonary Sarcoidosis
    • 10.1.6. Musculoskeletal Sarcoidosis
    • 10.1.7. Cutaneous Sarcoidosis
    • 10.1.8. Ocular Sarcoidosis
    • 10.1.9. Cardiac Sarcoidosis
    • 10.1.10. Neurosarcoidosis

11. Sarcoidosis Drug Market - By End-Use

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Use, 2024 & 2032 (%)
    • 11.1.2. Surgical Centers
    • 11.1.3. Hospitals & Clinics
    • 11.1.4. Diagnostic Centers
    • 11.1.5. Others

12. Sarcoidosis Drug Market - By Age Group

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 12.1.2. Pediatric
    • 12.1.3. Adult
    • 12.1.4. Geriatric

13. Sarcoidosis Drug Market - By Indication

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 13.1.2. Extrapulmonary Sarcoidosis
    • 13.1.3. Pulmonary Sarcoidosis

14. Sarcoidosis Drug Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Sarcoidosis Drug Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Sarcoidosis Drug Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Sarcoidosis Drug Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Sarcoidosis Drug Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Sarcoidosis Drug Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Sarcoidosis Drug Industry

  • 15.1. Competitive Benchmarking
    • 15.1.1. Competitive Dashboard
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Janssen Pharmaceutical Companies of Johnson & Johnson
    • 15.2.2. Pfizer Inc
    • 15.2.3. Amgen Inc.
    • 15.2.4. Bristol Myers Squibb
    • 15.2.5. Novartis AG
    • 15.2.6. Kinevant Sciences GmbH
    • 15.2.7. Molecure S.A
    • 15.2.8. aTyr Pharma
    • 15.2.9. Merck & Co., Inc
    • 15.2.10. Xentria
    • 15.2.11. United Therapeutics Corporation
    • 15.2.12. Relief Therapeutics
    • 15.2.13. Mallinckrodt
    • 15.2.14. AbbVie Inc.
    • 15.2.15. Kyorin Pharmaceutical Co., Ltd.
    • 15.2.16. Boehringer Ingelheim International GmbH
    • 15.2.17. Sanofi
    • 15.2.18. GSK plc.
    • 15.2.19. Theravance Biopharma
    • 15.2.20. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제